CNS tumor

Schall Law Firm seeks lead plaintiffs in class action against REGENXBIO for allegedly concealing negative efficacy and safety data on RGX-111 candidate drug.

REGENXBIO faces class action securities fraud lawsuit over allegedly concealed safety data for gene therapy RGX-111, triggered by CNS tumor discovery in clinical trial.

Schall Law Firm seeks $RGNX investors for securities fraud class action alleging false statements about RGX-111 candidate, following tumor discovery in trial participant.

Schall Law Firm seeks investors in $RGNX securities fraud class action over allegedly misleading statements about RGX-111 clinical trial data.

REGENXBIO faces securities fraud lawsuit over alleged misrepresentations about RGX-111's safety and efficacy. A CNS tumor discovery contradicted prior investor statements, causing shareholder losses.

REGENXBIO faces securities fraud lawsuit for allegedly making false statements about RGX-111 safety while withholding adverse trial data from investors between February 2022 and January 2026.

REGENXBIO faces securities lawsuit for allegedly misleading investors about RGX-111 gene therapy safety concerns. FDA imposed clinical hold after trial participant developed CNS tumor.